Prevention of venous thromboembolism in obesity

References

• Spyropoulos AC, Mahan C. Venous thromboembolism prophylaxis in the medical patient: controversies and perspectives. Am. J. Med.122, 1077–1084 (2009).
   PubMed Web of Science ®Google Scholar
• Spencer FA, Lessard D, Emery C, Reed G, Goldberg RJ. Venous thromboembolism in the outpatient setting. Arch. Intern. Med.167, 1471–1475 (2007).
   PubMed Web of Science ®Google Scholar
• Anderson FA Jr, Wheeler HB, Goldberg RJ et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch. Intern. Med.151, 933–938 (1991).
   PubMed Web of Science ®Google Scholar
• Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133, 381S–453S (2008).
   PubMed Web of Science ®Google Scholar
• Berlot G, Calderan C, Vergolini A et al. Pulmonary embolism in critically ill patients receiving antithrombotic prophylaxis: a clinical-pathologic study. J. Crit. Care DOI:10.1016/j.jcrc.2010.04.004 (2010) (Epub ahead of print).
   Google Scholar
• Samama MM, Cohen AT, Darmon JY et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N. Engl. J. Med.341, 793–800 (1999).
   PubMed Web of Science ®Google Scholar
• Spyropoulos AC. Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients. Chest128, 958–969 (2005).
   PubMed Web of Science ®Google Scholar
• Dhillon S, Plosker GL. Fondaparinux: use in thromboprophylaxis of acute medical patients. Drugs Aging25, 81–88 (2008).
   PubMed Web of Science ®Google Scholar
• Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation110, 874–879 (2004).
   PubMed Web of Science ®Google Scholar
• Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation117, 93–102 (2008).
   PubMed Web of Science ®Google Scholar
• Stein PD, Beemath A, Olson RE. Obesity as a risk factor in venous thromboembolism. Am. J. Med.118, 978–980 (2005).
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ, Grodstein F, Stampfer MJ et al. A prospective study of risk factors for pulmonary embolism in women. JAMA277, 642–645 (1997).
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ, Savage DD, Garrison RJ et al. Risk factors for pulmonary embolism. The Framingham Study. Am. J. Med.74, 1023–1028 (1983).
   PubMed Web of Science ®Google Scholar
• Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA303, 235–241 (2010).
   PubMed Web of Science ®Google Scholar
• Snell AM. The relation of obesity to fatal post-operative pulmonary embolism. Arch. Surg.15, 237–244 (1927).
   Google Scholar
• Hansson PO, Eriksson H, Welin L, Svardsudd K, Wilhelmsen L. Smoking and abdominal obesity: risk factors for venous thromboembolism among middle-aged men: ‘the study of men born in 1913’. Arch. Intern. Med.159, 1886–1890 (1999).
   PubMed Web of Science ®Google Scholar
• Kabrhel C, Varraso R, Goldhaber SZ, Rimm EB, Camargo CA. Prospective study of BMI and the risk of pulmonary embolism in women. Obesity (Silver Spring)17, 2040–2046 (2009).
   PubMed Web of Science ®Google Scholar
• Severinsen MT, Overvad K, Johnsen SP et al. Genetic susceptibility, smoking, obesity and risk of venous thromboembolism. Br. J. Haematol.149, 273–279 (2010).
   PubMed Web of Science ®Google Scholar
• Stein PD, Goldman J. Obesity and thromboembolic disease. Clin. Chest. Med.30, 489–493, viii (2009).
   PubMed Web of Science ®Google Scholar
• Eichinger S, Hron G, Bialonczyk C et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch. Intern. Med.168, 1678–1683 (2008).
   PubMed Web of Science ®Google Scholar
• Faber DR, de Groot PG, Visseren FL. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes. Rev.10, 554–563 (2009).
   PubMed Web of Science ®Google Scholar
• Napoleone E, A DIS, Amore C et al. Leptin induces tissue factor expression in human peripheral blood mononuclear cells: a possible link between obesity and cardiovascular risk? J. Thromb. Haemost.5, 1462–1468 (2007).
   PubMed Web of Science ®Google Scholar
• Bogdanov VY, Balasubramanian V, Hathcock J, Vele O, Lieb M, Nemerson Y. Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein. Nat. Med.9, 458–462 (2003).
   PubMed Web of Science ®Google Scholar
• Kopp CW, Kopp HP, Steiner S et al. Weight loss reduces tissue factor in morbidly obese patients. Obes. Res.11, 950–956 (2003).
   PubMedGoogle Scholar
• Ay L, Kopp HP, Brix JM et al. Thrombin generation in morbid obesity: significant reduction after weight loss. J. Thromb. Haemost.8, 759–765 (2010).
   PubMed Web of Science ®Google Scholar
• Hosogai N, Fukuhara A, Oshima K et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes56, 901–911 (2007).
   PubMed Web of Science ®Google Scholar
• Lopez JA, Chen J. Pathophysiology of venous thrombosis. Thromb. Res.123, S30–S34 (2009).
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin. Pharmacokinet.49, 71–87 (2010).
   PubMed Web of Science ®Google Scholar
• Imberti D, Legnani C, Baldini E et al. Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thromb. Res.124, 667–671 (2009).
   PubMed Web of Science ®Google Scholar
• Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest126, 188S–203S (2004).
   PubMed Web of Science ®Google Scholar
• Shepherd MF, Rosborough TK, Schwartz ML. Heparin thromboprophylaxis in gastric bypass surgery. Obes. Surg.13, 249–253 (2003).
   PubMed Web of Science ®Google Scholar
• Shepherd MF, Rosborough TK, Schwartz ML. Unfractionated heparin infusion for thromboprophylaxis in highest risk gastric bypass surgery. Obes. Surg.14, 601–605 (2004).
   PubMed Web of Science ®Google Scholar
• Quebbemann B, Akhondzadeh M, Dallal R. Continuous intravenous heparin infusion prevents peri-operative thromboembolic events in bariatric surgery patients. Obes. Surg.15, 1221–1224 (2005).
   PubMed Web of Science ®Google Scholar
• Samama MM, Verhille C, Carchy L. Relation between weight, obesity, and frequency of deep vein thrombosis after enoxaparin in orthopedic surgery. Thromb. Haemost.73, 977 (1995) (Abstract300).
   Google Scholar
• Tripodi A, van den Besselaar A. Laboratory monitoring of anticoagulation: where do we stand? Semin. Thromb. Hemost.35, 34–41 (2009).
   PubMed Web of Science ®Google Scholar
• Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J. Thromb. Haemost.2, 551–554 (2004).
   PubMed Web of Science ®Google Scholar
• Harenberg J. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes. J. Thromb. Haemost.2, 547–550 (2004).
   PubMed Web of Science ®Google Scholar
• Lim W. Using low molecular weight heparin in special patient populations. J. Thromb. Thrombolysis29, 233–240 (2010).
   PubMed Web of Science ®Google Scholar
• Sanderink GJ, Le Liboux A, Jariwala N et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin. Pharmacol. Ther.72, 308–318 (2002).
   PubMed Web of Science ®Google Scholar
• Wilson SJ, Wilbur K, Burton E, Anderson DR. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism. Haemostasis31, 42–48 (2001).
   PubMedGoogle Scholar
• Al-Yaseen E, Wells PS, Anderson J, Martin J, Kovacs MJ. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J. Thromb. Haemost.3, 100–102 (2005).
   PubMed Web of Science ®Google Scholar
• Bazinet A, Almanric K, Brunet C et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb. Res.116, 41–50 (2005).
   PubMed Web of Science ®Google Scholar
• Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br. J. Surg.90, 547–548 (2003).
   PubMed Web of Science ®Google Scholar
• Mayr AJ, Dunser M, Jochberger S et al. Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb. Res.105, 201–204 (2002).
   PubMed Web of Science ®Google Scholar
• Jimenez D, Diaz G, Iglesias A et al. Anti-factor Xa activity of enoxaparin for thromboprophylaxis in nonsurgical patients is dependent on body mass. Arch. Bronconeumol.44, 660–663 (2008).
   PubMed Web of Science ®Google Scholar
• Hainer JW, Barrett JS, Assaid CA et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb. Haemost.87, 817–823 (2002).
   PubMed Web of Science ®Google Scholar
• Rondina MT, Wheeler M, Rodgers GM, Draper L, Pendleton RC. Weight-based dosing of enoxaparin for VTE prophylaxis in morbidly obese, medically-ill patients. Thromb. Res.125, 220–223 (2010).
   PubMed Web of Science ®Google Scholar
• Rowan BO, Kuhl DA, Lee MD, Tichansky DS, Madan AK. Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes. Surg.18, 162–166 (2008).
   PubMed Web of Science ®Google Scholar
• Simone EP, Madan AK, Tichansky DS, Kuhl DA, Lee MD. Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. Surg. Endosc.22, 2392–2395 (2008).
   PubMed Web of Science ®Google Scholar
• Kucher N, Leizorovicz A, Vaitkus PT et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch. Intern. Med.165, 341–345 (2005).
   PubMed Web of Science ®Google Scholar
• Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes. Surg.12, 19–24 (2002).
   PubMed Web of Science ®Google Scholar
• Borkgren-Okonek MJ, Hart RW, Pantano JE et al. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity. Surg. Obes. Relat. Dis.4, 625–631 (2008).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch. Intern. Med.162, 1833–1840 (2002).
   PubMed Web of Science ®Google Scholar
• Agnelli G, Bergqvist D, Cohen AT, Gallus AS, Gent M. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br. J. Surg.92, 1212–1220 (2005).
   PubMed Web of Science ®Google Scholar
• Raftopoulos I, Cortese-Hassett A, Gourash W et al. Pharmacokinetic properties of fondaparinux sodium in morbidly obese volunteers indicate that a single, weight-independent daily dose for thromboprophylaxis is feasible. Presented at: Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). Philadelphia, PA, USA, 8–12 April 2008.
   Google Scholar
• Hamad GG, Choban PS. Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the Prophylaxis Against VTE Outcomes in Bariatric Surgery Patients Receiving Enoxaparin (PROBE) study. Obes. Surg.15, 1368–1374 (2005).
   PubMed Web of Science ®Google Scholar
• Turpie AG, Bauer KA, Caprini JA, Comp PC, Gent M, Muntz JE. Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison. J. Thromb. Haemost.9, 1854–1861 (2007).
   Google Scholar
• Sapala JA, Wood MH, Schuhknecht MP, Sapala MA. Fatal pulmonary embolism after bariatric operations for morbid obesity: a 24-year retrospective analysis. Obes. Surg.13, 819–825 (2003).
   PubMed Web of Science ®Google Scholar
• Wu EC, Barba CA. Current practices in the prophylaxis of venous thromboembolism in bariatric surgery. Obes. Surg.10, 7–13 (2000).
   PubMed Web of Science ®Google Scholar
• Barba CA, Harrington C, Loewen M. Status of venous thromboembolism prophylaxis among bariatric surgeons: have we changed our practice during the past decade? Surg. Obes. Relat. Dis.5, 352–356 (2009).
   PubMed Web of Science ®Google Scholar
• Rajasekhar A, Crowther M. Inferior vena caval filter insertion prior to bariatric surgery: a systematic review of the literature. J. Thromb. Haemost.8, 1266–1270 (2010).
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Cook DJ, Jaeschke R, Pauker SG, Schunemann HJ. Grades of recommendation for antithrombotic agents: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133, 123S–131S (2008).
   PubMed Web of Science ®Google Scholar
• Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest133, 141S–159S (2008).
   PubMedGoogle Scholar
• Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann. Pharmacother.43, 1064–1083 (2009).
   PubMed Web of Science ®Google Scholar
• Escalante-Tattersfield T, Tucker O, Fajnwaks P et al. Incidence of deep vein thrombosis in morbidly obese patients undergoing laproscopic Roux-en-Y gastric bypass. Surg. Obes. Relat. Dis.4, 126–130 (2008).
   PubMed Web of Science ®Google Scholar
• Magee CJ, Barry J, Javed S, Macadam R, Kerrigan D. Extended thromboprophylaxis reduces incidence of postoperative venous thromboembolism in laparoscopic bariatric surgery. Surg. Obes. Relat. Dis.6, 322–325 (2010).
   PubMed Web of Science ®Google Scholar